TUCSON, AZ--(Marketwire - February 17, 2009) -
| Highlighted Links |
http://www.cdexinc.com |
"FY08 was a year of positioning and great accomplishments for CDEX," said Malcolm Philips, CDEX CEO. "Even while we expanded significantly our existing ValiMed product line, introduced the new ID2 product line, and positioned ourselves for the future by increased R&D spending, we still reduced our net operating loss by over 18%. While the global economic downturn presents major challenges for every company, including CDEX, we are moving in the right direction and fully expect to be cash flow positive by the last quarter of 2009 -- our next major goal." (See expanded comments regarding FY08 in the Management Briefing Section of the CDEX Web Site at www.cdexinc.com.)
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts or illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must raise additional funds as stated periodically in its SEC filings. For more information, visit www.cdexinc.com.
Non-historical statements are forward-looking, as defined in federal
securities laws, and generally can be identified by words such as
"expects," "plans," "may," "believes," "should," "intends," and similar
words. These statements pose risks and uncertainties that cannot be
accurately predicted or quantified and, consequently, actual results may
differ materially from those expressed or implied. Such risks and
uncertainties include, without limitation, the effectiveness, profitability
and marketability of products, the protection of intellectual property and
proprietary information, and other risks detailed periodically in filings
with the SEC. There is no obligation to update any forward-looking
statements.
